These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 3510733

  • 1. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE, Herberman RB.
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract] [Full Text] [Related]

  • 2. Immunomodulatory and therapeutic properties of bestatin in mice.
    Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, Tribble H.
    Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI, Dobkin AI, Ryzhova EV, Okulov VB, Kiselev OI.
    Vopr Onkol; 1989 Sep; 35(2):141-50. PubMed ID: 2648678
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition by selected anticancer agents of the development of primary cell-mediated immunity against allogeneic tumor cells in culture.
    Orsini F, Eppolito C, Ehrke MJ, Mihich E.
    Cancer Treat Rep; 1980 Sep; 64(2-3):211-8. PubMed ID: 6967756
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P, De Meyer M, Leroy P, Rousseau C, Acres B.
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [Abstract] [Full Text] [Related]

  • 12. [Immunity and immunosuppression in tumor growth].
    Govallo VI.
    Vopr Onkol; 1987 May; 33(4):91-9. PubMed ID: 3296437
    [No Abstract] [Full Text] [Related]

  • 13. The NCI preclinical screen of biological response modifiers.
    Talmadge JE, Fidler IJ, Oldham RK.
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [Abstract] [Full Text] [Related]

  • 14. Enkephalins and endorphins as modifiers of the immune system: present and future.
    Wybran J.
    Fed Proc; 1985 Jan; 44(1 Pt 1):92-4. PubMed ID: 2981735
    [Abstract] [Full Text] [Related]

  • 15. [Interleukin 2].
    Voĭtenok NN.
    Ter Arkh; 1988 Jan; 60(5):42-6. PubMed ID: 3051488
    [No Abstract] [Full Text] [Related]

  • 16. A sequential multi-assay protocol for the preclinical assessment of natural product complex carbohydrate immunomodulators.
    Williams DL, Pretus HA, McNamee RB, Jones EL.
    Dev Biol Stand; 1992 Jan; 77():129-36. PubMed ID: 1426653
    [Abstract] [Full Text] [Related]

  • 17. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
    Kedar E, Zeira E, Lebendiker Z, Weiss DW, Katan R, Shouval D.
    Prog Clin Biol Res; 1987 Jan; 244():59-75. PubMed ID: 3498959
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effector immune mechanisms in cancer.
    Lotzová E.
    Nat Immun Cell Growth Regul; 1985 Jan; 4(6):293-304. PubMed ID: 3911064
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.